Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price fell 7.8% during trading on Tuesday . The stock traded as low as $0.33 and last traded at $0.33. 39,393,920 shares traded hands during trading, an increase of 28% from the average session volume of 30,856,506 shares. The stock had previously closed at $0.36.
Wall Street Analysts Forecast Growth
Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a report on Monday, December 23rd. They issued a "hold" rating for the company.
Check Out Our Latest Research Report on TNXP
Tonix Pharmaceuticals Stock Performance
The company's 50-day moving average is $0.23 and its two-hundred day moving average is $0.37. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07. The company has a market cap of $61.64 million, a P/E ratio of -0.01 and a beta of 2.23.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts' consensus estimates of ($2.03) by $1.80. The firm had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Read More
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
